Market · Life sciences talent
Life sciences licensing and collaboration counsel.
The received story is that biopharma dealmaking went quiet. The 2025 book says the structure moved. For a mid-cap general counsel the live question is who on the payroll owns the collaboration after the close: the milestone ledger, the sublicensing consents, the reversion trigger that decides whether the asset is still yours in year four.
The quiet-market story fails the 2025 book.
A company searching for licensing agreement counsel in Boston is usually deciding one of three staffing models: one in-house seat that both closes and administers, a split between a closer and an administrator, or a standing panel instruction. Pick the lens that matches the file you actually have.
EY’s 2026 Firepower report put signed US biopharma M&A at $240 billion in 2025, up 81 percent, while deal count fell 12 percent and average M&A size rose 107 percent. That is not a quiet market. It is a thicker instrument. Structure moved. Headcount stories lagged.
The hire is an owner of a live instrument, not a synonym for “life-sciences lawyer.” The post-signature file is unpacked below.
- 46
- FDA CDER novel drugs, 2025New molecular entities needing a commercial home
- FDA, Novel Drug Approvals for 2025
- 9 / 13
- IRA negotiation-eligibility yearsSmall molecule vs biologic, from approval or licensure
- KFF, Inflation Reduction Act explainer
- $2.1T
- Life-sciences dealmaking firepower, 2025Cash plus debt capacity, not deployed capital
- EY Firepower report, 2026 edition
- 27%
- Boston in-house counter-offer incidenceSartori Boston in-house line, trailing three years
- Sartori mandate telemetry
Dealmaking did not go quiet. The owner of the year-four file did not appear with it.
The 2025 book is a size-and-shape story. A general counsel who staffs against a vanished volume will under-hire the only part of the work that now sits on the payroll.
We have worked the Boston in-house market for eight years, for biotech, specialty-pharma and research-adjacent companies that license assets in and out. Over the trailing three years we closed 19 in-house searches on this line at a 93 percent completion rate, with a median of 15 working days from offer to acceptance. The live question on that book is not whether the cluster still does deals. It is whether anyone inside the company still owns them.
The received narrative — biopharma dealmaking went quiet — fails the 2025 arithmetic. EY’s 2026 Firepower report is the dated public record for signed US biopharma M&A and alliance (“biobucks”) forms. Value concentrated. Average size jumped. Upfront cash on alliances shrank to around 7 percent of total potential value, which means the rest of the headline sits in a milestone calendar a chief legal officer cannot treat as a closing souvenir. Alliance count did not rise; it fell from 245 to 228. Anyone who sells this year as a volume boom in collaborations is misreading the same table.
Evaluate, in November 2025, read the same year as a move toward fewer, higher-value licensing deals, with M&A following a similar path. That is the public confirmation of the opening angle. The structure moved. The owner of the year-four file did not appear with it. Option, tranche and territory-split forms replaced a share of outright acquisition because they are narrower, more contingent, and easier to defend to a board that has watched a full-entity purchase pick up an antitrust theory it did not budget for.
Out-licensing is not a slogan. The IQVIA Institute, in its 29 October 2025 study of emerging biopharma, counted 197 novel active substances first commercialized by 176 companies over roughly a decade. The bars below split that population into the three exits that actually occurred. The out-license-and-remain-independent path is a minority. It is also a standing legal file, not an event.
Boston is not insulated from the cluster’s employment contraction, and it is not a closed funding market either. MassBio’s January 2026 funding report put full-year 2025 venture capital to Massachusetts-headquartered biopharma companies at $6.85 billion across 197 rounds, described as a return to pre-pandemic levels, with 71 percent of that funding landing outside Cambridge and Boston out-raising Cambridge for a second consecutive year. Thirty-six Massachusetts companies were acquired in 2025 for a combined $20 billion. Two completed IPOs. The drug-candidate pipeline among Massachusetts-headquartered companies rose nearly 14 percent. A general counsel reading only the 3.1 percent employment decline will staff a quieter desk than the pipeline justifies.
Eight Massachusetts life-sciences companies completed IPOs in the first half of 2026, already matching the combined 2024 and 2025 full-year total and about 66 percent of all US biotech listings in the period, per MassBio’s 2026 Industry Snapshot. Eleven Massachusetts companies were acquired in that same half for $18.0 billion. Average Series A in the half was $79.6 million; average seed fell to $4.65 million from $7.65 million. The legal consequence is uneven: more late-stage instruments, fewer seed-stage term sheets, and a thicker post-close book on the deals that do sign.
Those Massachusetts assets still needed a commercial home. IQVIA’s Global Trends in R&D 2026, published 25 March 2026, sized the 2025 launch book that a general counsel would have had to house, in-license or out-license. The bars below are that census, not a hiring forecast.
London is the volatility contrast, not a second research program. The BioIndustry Association’s January 2026 financing report put UK biotech equity financing at £1.9 billion in 2025, down 49 percent, with zero IPOs for a third year. Its 20 July 2026 release then recorded £2.05 billion of UK biotech venture in the second quarter of 2026 alone — a five-year high that includes a £1.6 billion Series B; excluding that megadeal the quarter was £498 million. A London-facing in-license now prices against a compressed MHRA International Recognition Procedure clock, live since 1 January 2024, not against a steady local raise. Basel appears in public data as a formation and relocation market: 36 companies settled in the Basel Area in 2024, 26 of them in life sciences, per Basel Area Business & Innovation on 20 March 2025. That is a place name and a company-settlement count. It is not a legal-headcount series, and this page does not coin one.
Full-entity purchaseContingent collaboration
- Outright acquisition The company buys the equity. Antitrust, integration and a single closing file. The instrument ends.
- Option, tranche, territory split The company buys a path. Milestones, consents and reversions stay live for years. This is the 2025 default.
- Royalty finance and synthetic forms The company sells a cash-flow strip or a regional right and keeps the rest. Still an administered file.
The structure moved. The owner of the year-four file did not appear with it.
The in-house title is real. It is not one title.
A chief legal officer at a large-cap biotech, a general counsel at a mid-cap, and a tech-transfer office are buying three different desks. Write the requisition against the buyer you are, not against the practice label.
The Boston legal market we map is a coverage figure, not an interview count: roughly 3,500 lawyers, refreshed on the same quarterly cycle the research program has run since 2019. The people who actually hire this seat sit in four buyer types, and only the first two put a counsel title on the door.
Large-cap pharma and large public biotech
A named in-house function: Director or Senior Director, Corporate Counsel, Transactions, reporting toward an Assistant General Counsel and a Chief Legal Officer. Cambridge, Massachusetts recurs as a seat even when the requisition is budgeted elsewhere.
Mid-cap and specialty biotech
The same work sits one or two titles higher: Senior Director or Assistant General Counsel. Company size does not cleanly predict the band. The chief legal officer is often still the only lawyer who can sign.
Research institutes and tech-transfer offices
Licensing officers, not a titled counsel seat. MIT's Technology Licensing Office publishes a twelve-person licensing team and no attorney title on the public roster. Legal work is embedded, then rented.
The adjacent business seat, which is not this hire
Alliance management, corporate development and external-innovation roles sit next to the lawyer and do not carry a bar admission. Conflating the two is how a general counsel interviews the wrong shortlist.
Vertex Pharmaceuticals’ definitive proxy, filed with the SEC on 2 April 2026, titles the apex legal officer Chief Legal Officer. That is the public-company convention at a Boston-headquartered large-cap. Smaller and private companies still print General Counsel on the same chair. Either way, the specialist hire underneath is a transactions lawyer, not a second apex.
Regeneron’s Director, Corporate Counsel, Transactions posting, live on BioSpace on 3 September 2026, is the clean specimen of the large-cap seat: negotiate and draft sophisticated licensing, collaboration and services agreements, including structures with no precedent; support alliance management; manage the outside-counsel budget; attach a representative deal sheet. The role asked for a JD, a state bar (or registered in-house eligibility), and eight or more years negotiating complex biotech agreements. It did not ask for a patent bar. A separate Regeneron Senior Director, Corporate Counsel, Privacy/Transactions requisition sat in Cambridge, Massachusetts, inside a company whose primary transactions posting was budgeted at a New York headquarters. Sanofi listed Cambridge as one of three alternate locations on an Assistant General Counsel, Policy, Strategy & Litigation seat. The pattern is the overlay: the R&D hub is also the business-development legal hub.
Jazz Pharmaceuticals’ 2026 ladder — Senior Director, Senior Corporate Counsel, IP, up through Executive Director, Assistant General Counsel, Intellectual Property — shows where IP-titled seats sit relative to the apex. They are not this hire. Legend Biotech’s Patent Counsel posting required an undergraduate degree in the biological sciences and admission to practice before the USPTO. That lawyer supports diligence and drafts IP provisions. A general counsel who interviews that pool for a commercial-instrument seat will spend a quarter explaining the difference.
Research institutes run a third model. MIT’s Technology Licensing Office describes staff with deep knowledge of licensing, business development and legal matters, and publishes no distinct in-house counsel title inside the office. The legal work is real. The seat is not. A head of legal at a university-adjacent institute who opens a “licensing counsel” requisition is often forcing a corporate title onto a licensing-officer function that already exists — and that already has a panel.
The rented alternative still exists, and it is local. Boston offices of Goodwin Procter, Cooley, WilmerHale and Mintz all brand a standalone collaborations or technology-transactions practice, separate from general corporate and from patent prosecution. Mintz further labels a Royalty Finance sub-practice. That panel is how a general counsel should buy a first-of-kind option, a first China-originated in-license, or a first royalty strip. It is a poor substitute for the calendar on the third live deal.
| Seat | What the gate actually is | What the gate is not | Who is buying it |
|---|---|---|---|
| Transactions / collaborations counsel | JD, state bar, eight or more years drafting and negotiating complex biotech agreements; in-house experience preferred | USPTO registration; undergraduate life-science degree | General counsel filling a commercial-instrument seat |
| Patent counsel (adjacent, not a substitute) | JD, science undergraduate degree, USPTO registration, state bar, eight or more years of life-sciences prosecution | A closed collaboration as primary drafter | Chief legal officer who needs diligence support, not the closer |
| Alliance or corporate-development lead | Business or scientific pedigree; no bar admission in the postings reviewed | A law license or a deal sheet of negotiated instruments | Head of business development sitting beside legal, not instead of it |
Legend Biotech, Patent Counsel floor
USPTO and a science degree required — adjacent pool
BioSpace posting, 3 September 2026 ↗What the licensing agreement still requires after signature.
The scarce in-house skill is not another closer. It is the person who can still walk the instrument in year four.
Across 250 structured interviews with Boston in-house counsel, 68 of the 81 respondents sitting inside biotech or pharma legal departments over a 24-month window named post-signature administration — milestone ledgers, sublicensing consents, reversion triggers — as scarcer than another lawyer who could close. Thirty-four of those 81 still send a first-of-kind structure to a Boston panel. That split is the staffing model, stated as testimony rather than as a slogan.
A chief legal officer at a mid-cap public biotech, speaking from that same cohort, put it in one line: I can rent the close. I cannot rent the calendar. The panel will still take a first option, a first China-sourced in-license, a first royalty-finance strip. What the panel will not sit inside the building to do is watch a PDUFA-keyed milestone, a negotiation-eligibility step-down, and a sublicensing consent on the same Tuesday.
Cell-and-gene-therapy regulatory counsel is a different seat: that file is the biologics application and the advanced-therapy regulator, not this instrument. Med-tech and digital-health regulatory counsel is a device file. Name those desks for contrast; do not staff them from this shortlist, and do not staff this shortlist from theirs.
Close and leaveOwn the calendar
- Term-sheet closer Drafts the commercial instrument, hands the signed copy to the business, and returns to the next deal.
- Panel on retainer Outside counsel remains the memory of the deal. Fine for a first structure; expensive as a standing function.
- In-house owner Sits on the payroll. Runs the ledger, the consents and the reversion. This is the seat the 2025 forms created.
- Milestone notice calendar and payment mechanics
- Development-diligence reports and audit responses
- Sublicensing consent and revenue-share waterfall
- Reversion, termination and data hand-back
- Territory, most-favored pricing and tariff allocation
- Orange Book and listing warranties, with patent support
- Outside-counsel budget on the disputes the owner cannot swallow
| Workstream | What it is | How it fails | Who should own it |
|---|---|---|---|
| Milestone ledger | Development, regulatory and sales milestones keyed to IND, PDUFA dates, approval and, after the IRA, negotiation-eligibility dates | A missed notice window can forfeit a payment or trigger a diligence dispute | In-house once three or more live deals sit on the books |
| Diligence obligations | Use-it-or-lose-it development covenants, reporting packs, audit rights | Reversion or step-in if the licensee slows the program | In-house calendar; panel for a first dispute |
| Sublicensing consents | Consent rights, revenue-share waterfalls, change-of-control and assignment | A silent sublicense can strand economics or create a third-party fight | In-house; panel on a first-of-kind split |
| Reversion and termination | Triggers, data and inventory hand-back, surviving licenses, wind-down | Year four is when a general counsel discovers the asset is no longer theirs | In-house; this is the seat the closer does not automatically own |
| Territory and manufacturing clauses | Carve-outs, most-favored pricing, tariff-allocation and site-of-manufacture after the April 2026 Section 232 proclamation | A territory split that ignored the tariff line mis-prices the deal | Shared: panel on the first cross-border form, in-house on amendments |
| Orange Book and listing warranties | Representations on proper listing after the FTC's 2023-2025 enforcement program | Listing risk now sits inside the instrument, not only in a patent file | Transactions counsel with patent support; not patent counsel alone |
I can rent the close. I cannot rent the calendar.
The clocks that turned a closing into a standing function.
Antitrust risk, an exclusivity asymmetry, a tariff line and a patent cliff all push the same way: narrower instruments, longer administration.
Three forces pushed deal-makers toward option, tranche and territory-split forms, and each one deposits work on the in-house desk after the signature. The first is antitrust execution risk on portfolio-adjacent purchases. The Federal Trade Commission sued to block Amgen’s $27.8 billion acquisition of Horizon Therapeutics on 16 May 2023, on a cross-market bundling theory; the behavioral consent landed on 1 September 2023 and the final order on 14 December 2023. Boards that watched a non-overlapping pair pick up a live theory now route the next adjacent product through a collaboration. That raises the volume of instruments a head of legal has to administer, and it does not raise the volume of full-entity closings a panel wants to staff.
The same agency turned Orange Book listing validity into a diligence item inside the commercial instrument. The 14 September 2023 policy statement treated improper listings as a potential unfair method of competition under Section 5. Follow-through ran for two more years: more than 300 listings challenged on 30 April 2024, more than 200 renewed on 21 May 2025, and Teva’s removal of more than 200 listings covering more than 30 products on 10 December 2025. A transactions lawyer who leaves listing risk to a separate patent file is underwriting the 2022 version of this deal.
The second force is the Inflation Reduction Act’s negotiation clock, which KFF sets out as a hard-coded 9-year small-molecule and 13-year biologic eligibility test. The first ten negotiated Part D prices, selected on 1 September 2023, took effect on 1 January 2026. The next fifteen Part D drugs were selected on 1 February 2025, with prices effective 1 January 2027. Part B drugs enter from 2028, then twenty drugs a year. Royalty step-downs, diligence covenants and reversion triggers now key off a negotiation-eligibility date that did not exist as a deal term before the statute. A chief legal officer whose last in-house transactions hire came up on patent-cliff logic alone is missing a clock.
The third force is a capital cycle in which a cash-constrained biotech sells a right instead of selling the company. Biohaven’s 26 August 2026 out-license of an epilepsy program and ion-channel platform — $350 million upfront, a $50 million year-two payment, up to $150 million in development and regulatory milestones, assumption of up to $245 million of obligations, and mid-teens to low-twenties royalties, for $795 million plus royalties — is a single dated illustration, not a base rate. BioPharma Dive recorded it as a way to raise non-dilutive cash after clinical setbacks. MeiraGTx’s royalty-financing arrangement with Oberland Capital, reported by BioPharma Dive on 7 July 2026 at up to $400 million against eye gene-therapy programs, is the adjacent synthetic form: not M&A, not a classical bilateral license, still an administered file.
Government policy is now a counter-party to the same shift. The Section 232 pharmaceutical tariff proclamation of 2 April 2026 forces manufacturing-location and tariff-allocation clauses into cross-border collaborations; BIO warned the same day that small and mid-size biotechs, which it says develop over half of FDA-approved medicines, lack dedicated manufacturing capacity and will feel the line first. Executive Order 14297, signed 12 May 2025, directed HHS to communicate most-favored-nation price targets within 30 days and put importation and enforcement tools behind the request. Territory carve-outs stop being boilerplate. PDUFA VII runs through 30 September 2027; BIO endorsed the PDUFA VIII commitment letter on 13 August 2026. Milestone language keyed to a PDUFA date now carries a reauthorization contingency a post-signature seat has to track.
Cross-border origin is no longer a specialty overlay. BioPharma Dive, citing Jefferies, put China-sourced assets at one-third of 2025 industry licensing spend; the underlying bank note was not opened here, so the figure stays secondhand. Roche’s 24 August 2026 Hanmi license — $190 million upfront, up to $2.3 billion, worldwide rights excluding South Korea — is one dated territory-split specimen. IQVIA’s March 2026 R&D trends report said China-international biopharma R&D deals reached an all-time high without publishing the count in the excerpt we have. For a Boston general counsel in-licensing a China-originated program, export-control screening and cross-jurisdiction IP diligence are baseline, not a panel surprise.
Two European clocks matter only as they land on a Boston or Basel-headquartered counterpart. The Commission’s general pharmaceutical legislation proposal, COM(2023)0192 of 26 April 2023, spent three years in flux; the European Parliament voted a trilogue mandate on 16 June 2025 and a committee approved negotiated text on 18 March 2026. Exclusivity-contingent drafting is now a habit, not a one-off. The UK Life Sciences Sector Plan of 16 July 2025 commits government to land at least one major strategic partnership a year and cites a BioNTech partnership of up to £1 billion over ten years, aimed at up to 10,000 UK patients by 2030. That is a London-facing public-sector collaboration category. It is not this page’s subject, and it is not a reason to staff a Boston seat from a government-affairs shortlist.
National lab real estate is a caution, not a Boston census. JLL’s 23 September 2025 outlook put US life-sciences lab vacancy at 27 percent, up 20.4 percentage points over three years, with lab leasing down about 8 percent a year and sector venture down about 12 percent a year. Those are national rates and a different window from MassBio’s Massachusetts-specific first-half 2026 snapback. They do not cancel the pipeline. They do warn a head of legal not to treat every empty lab as an empty legal book.
| Driver | Instrument | Dated | What it does to the seat |
|---|---|---|---|
| Antitrust execution risk on portfolio M&A | FTC v. Amgen / Horizon Therapeutics | 2023 | Boards route adjacent products through option and collaboration forms instead of a full-entity purchase |
| Orange Book listing as a diligence item | FTC Section 5 policy and follow-through challenges | 2023-2025 | Every small-molecule in-license now underwrites listing risk inside the representations |
| Medicare negotiation eligibility | Inflation Reduction Act pill penalty | First prices 2026 | Royalty step-downs and reversions key off a 9-year or 13-year clock, not patent expiry alone |
| Cross-border tariff allocation | Section 232 pharmaceutical proclamation | April 2026 | Manufacturing-location and cost-allocation clauses become standing terms on territory-split deals |
| US / ex-US price arbitrage | Executive Order 14297, most-favored-nation targets | May 2025 | Territory carve-outs and price-adjustment mechanics stop being boilerplate |
| Patent-expiry replacement | Evaluate 2025-2030 exclusivity wall | 2025-2030 | In-licensing stays a multi-year demand engine even when employment in the cluster contracts |
One seat, two seats, or a panel — write the model before the brief.
Of the Boston licensing mandates we closed, the searches that slipped were the ones that arrived as a title. The ones that closed on the typical clock arrived as a file.
Of 19 closed Boston in-house searches over three years, 11 were life-sciences licensing or collaboration seats. Six of those 11 were briefed as a single seat that both negotiated and administered. Three were split: a closer and a separate owner for the ledger. Two were “close, then return to the panel.” Four of the 11 were re-briefed after the first shortlist because the company had specified a closer and still had no owner for the year-four file. Two of the 11 ran past the seven-month end of our typical window; both arrived without a decided staffing model. That last number cuts against us. We accepted the brief anyway.
A head of legal at a PE-backed specialty-pharma platform, speaking from the same Boston interview cohort, told us the first shortlist was full of people who had “assisted on” licenses. None could walk a reversion trigger cold. We have eight years of Boston in-house work on this line; the miss was not a thin market. It was a brief that bought a label.
EventStanding function
- Panel instruction Right for a first-of-kind option, a first China-originated in-license, or a first royalty strip. Wrong as the memory of the third live deal.
- Two seats A closer and an administrator. Honest when volume justifies it. Expensive when the closer still will not touch the calendar.
- One owner Negotiate and administer in the same in-house chair. The default once three or more collaborations sit on the books.
Two composite mandates
A mid-cap public biotech with a Cambridge-adjacent legal desk came to us with three live collaborations, all closed by a Boston panel over the previous eighteen months, and no one on payroll who could run the combined milestone calendar. The brief originally asked for “transactions counsel, eight years.” We rewrote it as an owner of three named instruments. Time-to-fill: five months, inside the four-to-seven-month typical window. The hire was an assistant general counsel moving from another public biotech. Counter-offer pressure arrived, consistent with the 27 percent incidence on this Boston line; the candidate signed on day fourteen.
A pharma business-unit legal team needed a territory-split in-license of a China-originated asset after the April 2026 tariff proclamation, with manufacturing-location and cost-allocation clauses that did not exist on their 2023 form. They rented the first close. They then opened an in-house seat because two more in-licenses sat behind it. We took that second brief past seven months. The company had not decided whether the new lawyer reported to the business-unit counsel or to the corporate chief legal officer, and we should have refused to launch until they had. The eventual hire was an in-house transactions lawyer already sitting in the cluster, not a firm-side closer.
Bring the seat onto the payroll when three or more live collaborations share a calendar, or when a personal signature sits on a diligence or listing representation.
- Write the file, not the title. Name the instruments, the clocks and the reporting line before you name the seniority.
- Budget the counter-offer. Sartori’s Boston in-house line records a 27 percent incidence. Incumbent employers defend a transactions lawyer who already holds the ledger.
- Separate patent support from the commercial owner. USPTO registration is a different gate. Do not interview that pool for this chair.
- Put Cambridge in the location set if the science sits there. Multi-site companies already do. A remote-only brief will lose the people who run the live alliances.
- Use the panel for the first novel form. Then stop using it as the memory of the deal.
Keep a standing instruction for first-of-kind structures, and for the institute buyer that never titled a counsel seat at all.
- First option, first royalty strip, first China-originated in-license. Those are panel files. A lean in-house team will spend the close learning the form.
- Tech-transfer offices. A twelve-person licensing-officer bench with embedded legal work does not become better by forcing a corporate counsel title onto it.
- Disputes and first reversions. The in-house owner still needs a panel when the file becomes a fight. Budget that. Do not pretend the owner replaces litigation counsel.
- Do not rent the calendar. Once the third live deal is on the books, hourly memory is the expensive option, not the safe one.
- The service view of the same Boston book sits on our Boston in-house counsel recruiting page.
- Q1 Can you name the instruments already live, and the clocks they run on? If the brief is only “life-sciences transactions, eight years” → you will buy a closer and still have no calendar.
- Q2 Have you chosen one in-house owner, a split, or a panel — and who the hire reports to? If the reporting line is still a negotiation between a business unit and the chief legal officer → do not open the search.
- Q3 Does at least one shortlisted lawyer already own a collaboration they can walk without notes? If every CV is “assisted on” → budget a supervised ramp, or keep the panel for one more cycle.
- → All three clear? Run a confidential in-house search against the file, not the label.
| Factor | What to interrogate | Weighs most for |
|---|---|---|
| Closed instrument as primary drafter | A collaboration, option, territory-split or royalty-finance agreement the candidate walked as lead, not a joinder or a due-diligence memo. | Every in-house transactions seat |
| Post-signature administration | A milestone calendar they actually ran, a sublicensing consent they issued, a reversion they navigated. | The year-four file |
| IRA and exclusivity literacy | Whether royalty and reversion language has been keyed to negotiation-eligibility dates, not only to patent expiry. | Small-molecule books |
| Cross-border and China-originated files | Export-control screening, forex, and a territory split they can walk without notes. | In-licensing desks at Boston and Basel-headquartered companies |
| Manufacturing and tariff clauses | Site-of-manufacture and cost allocation drafted after April 2026, not recycled from a 2023 form. | Territory-split and supply-adjacent deals |
| Side of the table | In-licensor, out-licensor, or both. A general counsel hiring an owner needs both; a panel instruction can be one-sided. | Mid-cap biotech |
| What this is not | A patent-prosecution book, a freedom-to-operate opinion practice, or an advanced-therapy regulatory file. Those seats sit next door. | Scope control |
Companies building a legal function from nothing, rather than adding a transactions seat under a sitting general counsel, should start with the first general counsel guide and with what companies look for in a new general counsel. The sequencing questions there come before anything on this page. The general in-house pay table lives on in-house counsel salary 2026; this article records only the disclosed posting bands for the transactions chair.
Common questions about life sciences licensing and collaboration counsel
Should our general counsel hire an owner for a licensing agreement, or keep the panel?
Hire the owner once three or more live collaborations sit on the books; rent the first novel structure. Sartori’s Boston in-house telemetry closed 11 licensing or collaboration seats inside 19 mandates over three years, and four of those 11 had to be re-briefed because the company had bought a closer and still had no one on payroll to run the milestone ledger.
Did biopharma dealmaking actually go quiet in 2025?
No. Signed US biopharma M&A value reached $240 billion in 2025, up 81 percent, while deal count fell 12 percent, according to EY’s 2026 Firepower report. Alliance average size rose 46 percent, with upfront cash around 7 percent of total potential value. The cash commitment and the instrument moved. Headline alliance count did not: 228 deals in 2025 against 245 in 2024.
What does a Boston in-house licensing or collaboration counsel seat pay?
No function-specific published survey band exists for this seat; disclosed 2026 postings sit between $205,000 and $341,600. Regeneron’s Director, Corporate Counsel, Transactions role advertised that range on BioSpace as of 3 September 2026 and asked for eight or more years negotiating complex biotech agreements. A small-cap Assistant General Counsel posting sat at $300,000 to $305,000. Treat those as advertised ranges, not as salaries paid.
How long does it take to fill this in-house seat in Boston?
Budget four to seven months on Sartori’s Boston in-house line. That is the typical time-to-fill across 19 closed searches over three years, at a 93 percent completion rate, with a median 15 working days from offer to acceptance. Counter-offers appear on 27 percent of those processes. The clock stretches when the company has not decided whether the hire owns the file after signature.
How is licensing and collaboration counsel different from patent counsel?
Patent counsel needs a science degree and USPTO registration; transactions counsel needs eight or more years drafting the commercial instrument. Legend Biotech’s 2026 Patent Counsel posting required an undergraduate biological-sciences degree and admission to practice before the USPTO, in a $168,372 to $220,988 band. Regeneron’s transactions posting required neither. They are adjacent hiring pools, not substitutes.
Does a research institute hire this counsel onto the payroll?
Often no. MIT’s Technology Licensing Office lists a 12-person licensing team under an Associate Director of Licensing, with no attorney title on the public roster. At that buyer type the legal work is embedded in a licensing-officer function and rented to a panel when a novel structure appears. A biotech general counsel is making a different decision.
Firepower figures, the IRA clock and the Boston research book.
Deal values and alliance counts come from EY and Evaluate. Exclusivity and listing mechanics come from the FTC, KFF and the named statutes. Boston employment and funding come from MassBio. In-house title and pay evidence comes from SEC filings and disclosed 2026 postings.
Sources & further reading
41 references- Sartori & Partners — Boston Legal Talent Research Programme (250 structured interviews; ~3,500 lawyers mapped; quarterly surveys since 2019; mandate telemetry) sartoriglobal.com ↗
- EY — Firepower report: life sciences dealmaking (2026 edition, full-year 2025 data) ey.com ↗
- FDA — Novel Drug Approvals for 2025 (current as of 8 July 2026) fda.gov ↗
- IQVIA Institute — Global Trends in R&D 2026 (25 March 2026) iqvia.com ↗
- IQVIA Institute — Expanding Options for Emerging Biopharma in the US: A Decade of Change (29 October 2025) iqvia.com ↗
- MassBio — 2026 Industry Snapshot massbio.org ↗
- MassBio — Biopharma Funding Report (January 2026, full-year 2025 data) massbio.org ↗
- BIA / biotechfinance.org — UK Biotech Financing Report 2025 (January 2026) biotechfinance.org ↗
- BIA — UK biotech venture investment reaches five-year high in Q2 2026 (20 July 2026) bioindustry.org ↗
- Basel Area Business & Innovation — Life sciences page (20 March 2025) baselarea.swiss ↗
- JLL — US Life Sciences market outlook (23 September 2025) jll.com ↗
- Evaluate — Portfolio Tactics to Scale the $300bn Patent Cliff (13 October 2025) evaluate.com ↗
- Evaluate — Pharma Dealmaking: Revealing Tomorrow's Therapies (19 November 2025) evaluate.com ↗
- FTC — Sues to Block Amgen Acquisition of Horizon Therapeutics (16 May 2023) ftc.gov ↗
- FTC — Approves Final Order Settling Horizon Therapeutics Acquisition Challenge (14 December 2023) ftc.gov ↗
- FTC — Policy Statement on Improper Listing of Patents in the Orange Book (14 September 2023) ftc.gov ↗
- FTC — Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings (30 April 2024) ftc.gov ↗
- FTC — Renews Challenge of More Than 200 Improper Patent Listings (21 May 2025) ftc.gov ↗
- FTC — Teva Removes Over 200 Improper Patent Listings (10 December 2025) ftc.gov ↗
- KFF — Explaining the Prescription Drug Provisions in the Inflation Reduction Act kff.org ↗
- MHRA — International Recognition Procedure gov.uk ↗
- European Commission — Pharmaceutical strategy / general pharmaceutical legislation reform health.ec.europa.eu ↗
- European Parliament Legislative Observatory — procedure 2023/0132(COD) oeil.europarl.europa.eu ↗
- HM Government — Life Sciences Sector Plan gov.uk ↗
- BIO — Statement on the Section 232 Pharmaceutical Proclamation (2 April 2026) bio.org ↗
- BIO — Supports PDUFA VIII Commitment Letter (13 August 2026) bio.org ↗
- Executive Order 14297 — Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients (12 May 2025) whitehouse.gov ↗
- BioPharma Dive — Drugs from China are reshaping biotech. Track the licensing deals here. biopharmadive.com ↗
- BioPharma Dive — Roche commits to lean-mass preservation with Hanmi obesity deal (24 August 2026) biopharmadive.com ↗
- BioPharma Dive — Biohaven trades cash for 'upside' with $795M epilepsy drug deal (26 August 2026) biopharmadive.com ↗
- BioPharma Dive — Deals topic page (illustrative 2026 structures, accessed 3 September 2026) biopharmadive.com ↗
- BioSpace — Director Corporate Counsel Transactions (Regeneron), posting live 3 September 2026 jobs.biospace.com ↗
- BioSpace — Patent Counsel / Senior Patent Counsel (Legend Biotech), posting live 3 September 2026 jobs.biospace.com ↗
- Vertex Pharmaceuticals — DEF 14A (filed 2 April 2026), Chief Legal Officer title sec.gov ↗
- MIT Technology Licensing Office — Our team tlo.mit.edu ↗
- MIT Technology Licensing Office — About tlo.mit.edu ↗
- Goodwin Procter — Life Sciences Collaborations & Licensing (practice page, landscape) goodwinlaw.com ↗
- Cooley — Life Sciences and Healthcare (practice page, landscape) cooley.com ↗
- WilmerHale — Technology Transactions and Licensing (practice page, landscape) wilmerhale.com ↗
- Mintz — Licensing & Technology Transactions (practice page, landscape) mintz.com ↗
- Sartori & Partners — In-house counsel recruiting in Boston ↗
EY Firepower figures are full-year 2025 as reported in the 2026 edition; the 7 percent upfront ratio is used and the paired absolute-dollar split is not. MassBio employment and funding series are Massachusetts-specific; JLL vacancy is a national lab-real-estate series and a different window. Evaluate patent-cliff and dealmaking reads are industry intelligence, not a lawyer census. The China-sourced spend share is Jefferies as cited by BioPharma Dive. Biohaven, Roche-Hanmi and MeiraGTx-Oberland are single dated transactions used as structure illustrations. Posting bands are advertised ranges as of 3 September 2026. Sartori interview, telemetry and counter-offer figures are the Boston in-house program constants and the subsets described in the body.
Our own numbers — the Boston interview cohort, the mandate telemetry, the counter-offer incidence and the offer-to-acceptance window — come from the continuous research program described on our research page, which sets out the survey waves and the mapping coverage behind every Sartori figure quoted above.
Adjacent maps for the same buyer.
The licensing seat sits under a general counsel, next to the whole-specialism demand map and the general in-house pay table. Those pages own those questions; this one owns the instrument.
Is Life Sciences Law Hiring in 2026?
The whole-specialism supply-and-demand read. This page does not re-argue that map; it develops the in-house licensing seat the other piece only names.
Read the specialism mapWhat Companies Look for in a New General Counsel
The buyer brief for the apex legal seat: scope, reporting line and the cuts a board actually makes, before a specialist transactions hire is even open.
Read the GC briefIn-House Counsel Salary 2026
The general in-house compensation table. This article does not own that grid; it only records the disclosed posting bands for the transactions seat.
Read the in-house pay tableA quiet conversation
Filling an in-house licensing or collaboration seat in Boston?
We map in-house transactions counsel for biotech, specialty-pharma and research-adjacent companies, and we are as willing to tell you the brief is a closer when you need an owner as to open a search. Confidential, no obligation.